ReViral, a biotechnology company aiming to help patients infected with respiratory syncytial virus (RSV) by developing novel compounds, is pleased to announce the appointment of Eddy Littler as CEO.
Eddy joins ReViral from Domainex, a UK-based drug discovery company, where as CEO he successfully delivered major growth in size, revenues and profit during his 9 years in charge. Eddy also managed the preclinical development of the Domainex drug pipeline.
During his distinguished career, Eddy has held senior positions in research and management in the pharmaceutical & biotech industries as well as in academia. He played a leading role in the development of several marketed drugs for herpes viruses, influenza, and viral hepatitis.
While leading the antiviral team at Medivir, he played a principal role in outlicensing Simeprevir, a treatment for hepatitis C to J&J. Dr Littler holds a PhD from the University of Leeds, UK, and is an expert in virology and drug discovery.
'We are delighted that Eddy Littler is joining ReViral as Chief Executive Officer,' commented Ken Powell, Chairman of ReViral. 'He is a tried and tested entrepreneurial business leader. His industry knowledge, track record and strong relationships are ideal skills to bring to ReViral. Eddy’s expertise in the antiviral area, leadership and experience are of significant benefit to the company.'
Eddy Littler commented: 'I am pleased to be joining ReViral as CEO at this critical time in its development when I can help to move the company’s lead programme, RV521, forward into clinical development. The groundbreaking projects and drug candidates at ReViral to treat RSV can translate into significant value for patients, clinicians and ReViral shareholders, and I look forward to contributing to the success of the company.'
